Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 34c, Beats on Revenue; Offers FY25 Revenue Guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.68, $0.34 better than the analyst estimate of $0.34. Revenue for the quarter came in at $141.4 million versus the consensus estimate of $131.54 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $557.2 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• Apple announced foldable iPhone Duo, starting at $1,999
• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Signet shares jump on Q2 profit beat, raised annual guidance